NeutroSpec Withdrawn For Safety Reasons Shortly After “Dear Doctor” Letter
FDA requested the market withdrawal of Palatin/Mallinckrodt's NeutroSpec less than three weeks after the companies issued a "Dear Healthcare Provider" letter addressing potential safety concerns with the imaging agent
You may also be interested in...
Biogen Idec and Elan are convening a panel of experts on progressive multifocal leukoencephalopathy as the first step towards reintroducing the multiple sclerosis therapy Tysabri (natalizumab)
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials